A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan.

Trial Profile

A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Methylnaltrexone bromide; Methylnaltrexone bromide; Paroxetine
  • Indications Constipation; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Focus Pharmacokinetics
  • Sponsors Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top